EZH2: biology, disease, and structure-based drug discovery

Citations Over TimeTop 10% of 2013 papers

Abstract

EZH2 is the catalytic subunit of the polycomb repressive complex 2 (PRC2), which is a highly conserved histone methyltransferase that methylates lysine 27 of histone 3. Overexpression of EZH2 has been found in a wide range of cancers, including those of the prostate and breast. In this review, we address the current understanding of the oncogenic role of EZH2, including its PRC2-dependent transcriptional repression and PRC2-independent gene activation. We also discuss the connections between EZH2 and other silencing enzymes, such as DNA methyltransferase and histone deacetylase. We comprehensively address the architecture of the PRC2 complex and the crucial roles of each subunit. Finally, we summarize new progress in developing EZH2 inhibitors, which could be a new epigenetic therapy for cancers.

Related Papers

• → Weaver Syndrome‐Associated EZH2 Protein Variants Show Impaired Histone Methyltransferase Function In Vitro(2015)85 cited
• → Noncanonical Functions of the Polycomb Group Protein EZH2 in Breast Cancer(2021)42 cited
• → Inhibition of Polycomb Repressive Complex 2 activity reduces trimethylation of H3K27 and affects development in Arabidopsis seedlings(2019)20 cited
• → Automethylation of PRC2 promotes H3K27 methylation and is impaired in H3K27M pediatric glioma(2019)115 cited
• → The Interaction between Histone Lysine Methyltransferase GLP and EZH2(2023)